Want to see IN:ONESOURCE full AI Analyst Report?
ONESOURCE Stock Chart & Stats
₹1653.40
₹35.00(2.12%)
At close: 4:00 PM EDT
₹1653.40
₹35.00(2.12%)
Day’s Range― - ―
52-Week Range₹1,075.00 - ₹1,924.00
Previous CloseN/A
Volume717.16K
Average Volume (3M)3.94K
Market Cap
₹177.93B
Enterprise Value₹222.64K
Total Cash (Recent Filing)₹1.80B
Total Debt (Recent Filing)₹12.95B
Price to Earnings (P/E)―
Beta0.40
Next Earnings
Nov 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)9.53
Shares Outstanding114,669,990
10 Day Avg. Volume3,856
30 Day Avg. Volume3,937
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.89
Price to Sales (P/S)11.87
P/FCF Ratio-24.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)36.13
Revenue Forecast (FY)₹22.53B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthA ~77% revenue surge in FY2026 indicates material top-line momentum and stronger market traction. Durable revenue expansion can support scale economies, future margin recovery, and reinvestment capacity if maintained, underpinning strategic growth over the next 2–6 months.
Manageable LeverageA historically low debt-to-equity (~0.16 in FY2025) and a sizeable equity base give the company financial flexibility to weather near-term losses. This structural balance sheet strength supports access to capital and strategic options while cash flows recover or investments scale.
Operating Scale & Industry ExposureA workforce of ~1,412 and positioning in biotechnology suggests established operating capability across development, manufacturing, or commercialization. This operational scale and exposure to structural biotech demand support sustained product development and market access over coming months.
Bears Say
Negative Cash GenerationConsistent negative operating and free cash flow, worsening in FY2026, signifies the business is burning cash to fund operations and investment. Over a 2–6 month horizon this raises financing dependency, limits reinvestment flexibility, and increases execution risk if cash generation doesn't improve.
Profitability DeteriorationA swing to a large net loss and materially weaker EBIT despite revenue growth indicates margin pressure and rising costs. Persistent profitability erosion can deplete reserves, hinder reinvestment, and necessitate restructuring or higher-cost financing over the medium term.
Rising Debt With LossesDebt rising at the same time profitability turned negative elevates leverage and refinancing risk. Even from a low base, increased debt plus cash burn strains financial flexibility and could force dilutive or costly funding choices if operating cash flows do not recover within months.
OneSource Specialty Pharma Limited News
ONESOURCE FAQ
What was OneSource Specialty Pharma Limited’s price range in the past 12 months?
OneSource Specialty Pharma Limited lowest stock price was ₹1075.00 and its highest was ₹1924.00 in the past 12 months.
What is OneSource Specialty Pharma Limited’s market cap?
OneSource Specialty Pharma Limited’s market cap is ₹177.93B.
When is OneSource Specialty Pharma Limited’s upcoming earnings report date?
OneSource Specialty Pharma Limited’s upcoming earnings report date is Nov 17, 2026 which is in 93 days.
How were OneSource Specialty Pharma Limited’s earnings last quarter?
OneSource Specialty Pharma Limited released its earnings results on Jul 24, 2026. The company reported ₹2.6 earnings per share for the quarter, missing the consensus estimate of ₹5.3 by -₹2.7.
Is OneSource Specialty Pharma Limited overvalued?
According to Wall Street analysts OneSource Specialty Pharma Limited’s price is currently Overvalued.
Does OneSource Specialty Pharma Limited pay dividends?
OneSource Specialty Pharma Limited does not currently pay dividends.
What is OneSource Specialty Pharma Limited’s EPS estimate?
OneSource Specialty Pharma Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OneSource Specialty Pharma Limited have?
OneSource Specialty Pharma Limited has 114,669,990 shares outstanding.
What happened to OneSource Specialty Pharma Limited’s price movement after its last earnings report?
OneSource Specialty Pharma Limited reported an EPS of ₹2.6 in its last earnings report, missing expectations of ₹5.3. Following the earnings report the stock price went down -0.024%.
Which hedge fund is a major shareholder of OneSource Specialty Pharma Limited?
Currently, no hedge funds are holding shares in IN:ONESOURCE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
OneSource Specialty Pharma Limited
OneSource Specialty Pharma Limited is a biopharmaceutical company focused on the discovery, advancement, production, and market introduction of biological drug products, primarily offered in diverse injectable formulations. The company conducts its operations internationally, with a footprint in India, Ireland, and the United States. It delivers comprehensive contract development and manufacturing (CDMO) services for biologics, encompassing all phases from preclinical and clinical development to commercial-scale supply. Its offerings extend to integrated drug-device systems such as pre-filled syringes, various pen injectors (including dial, push, and pull-push types for both variable and fixed doses), and autoinjectors. Furthermore, OneSource Specialty Pharma manufactures sterile injectable drugs and soft gelatin capsules, and provides specialized biologics solutions tailored for microbial and mammalian cell-line biopharmaceuticals, as well as for cell, gene, and RNA therapies. Established in 2007, the company, headquartered in Bengaluru, India, was formerly known as Stelis Biopharma Limited until its rebranding in February 2024.
Technical Analysis
Alembic Pharmaceuticals Limited
―
AstraZeneca Pharma India Limited
―
Eris Lifesciences Ltd
―
PFIZER LIMITED
―
Piramal Pharma Limited
―